Log In
BCIQ
Print this Print this
 

EDO-772P (EDO-772P/B776)

  Manage Alerts
Collapse Summary General Information
Company Mundipharma International Ltd.
DescriptionAntibody-drug conjugate (ADC) against CA 125
Molecular Target CA 125
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard IndicationOvarian cancer
Indication DetailsTreat ovarian cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today